- /
- Supported exchanges
- / US
- / QGEN.NYSE
Qiagen NV (QGEN NYSE) stock market data APIs
Qiagen NV Financial Data Overview
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Qiagen NV (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Qiagen NV data using free add-ons & libraries
Get Qiagen NV Fundamental Data
Qiagen NV Fundamental data includes:
- Net Revenue: 2 090 M
- EBITDA: 728 M
- Earnings Per Share: 2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-04
- EPS/Forecast: 0.59
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Qiagen NV News
New
Is New TB Data and AI Investment Altering The Investment Case For Qiagen’s QuantiFERON Platform (QGEN)?
Qiagen recently highlighted new clinical and health economic data backing its QuantiFERON-TB Gold Plus blood test for tuberculosis detection in high-risk and immunocompromised patients, alongside ongo...
Qiagen Announces Form 20-F Annual Report Filing for 2025 Results
VENLO, the Netherlands, March 20, 2026--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated...
Liquid Biopsy Products Market Report 2026-2031 Featuring Analysis of Roche, Illumina, Qiagen, MDxHealth, Novogen, BGI, Myriad Genetics and More
Company Logo Dublin, March 20, 2026 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Product Market Report: Trends, Forecast and Competitive Analysis to 2031" has been added to ResearchAndMarkets.com's offeri...
QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention
New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings Findings show QuantiFERON testing is cost-effective compared with tuberculin sk...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.